RVMD - Revolution Medicines - Stock & Dividends

Exchange: USA Stocks • Country: United States • Currency: USD • Type: Common Stock • ISIN: US76155X1000

Cancer, RAS, Inhibitors, Oncology, Therapies

Revolution Medicines Inc. is a clinical-stage precision oncology company that focuses on developing innovative targeted therapies for RAS-addicted cancers, a type of cancer that is driven by mutations in the RAS gene.

The company's research and development pipeline is built around two main areas: RAS(ON) inhibitors and RAS companion inhibitors. RAS(ON) inhibitors are designed to target specific mutations in the RAS gene, such as G12C, G12D, and G12V, and can be used as a single therapy or in combination with other RAS(ON) inhibitors or therapeutic agents. The company has several RAS(ON) inhibitors in various stages of clinical trials, including RMC-6236, RMC-6291, and RMC-9805, which are in phase 1 clinical trials.

In addition to RAS(ON) inhibitors, Revolution Medicines is also developing RAS companion inhibitors, which are designed to be used in combination with other therapies to enhance their effectiveness. The company's RAS companion inhibitors, such as RMC-4630 and RMC-5552, are in phase 2 and phase 1 clinical trials, respectively.

Revolution Medicines was founded in 2014 and is headquartered in Redwood City, California. The company's mission is to develop innovative therapies that can improve the lives of patients with RAS-addicted cancers. With a strong pipeline of promising drug candidates, Revolution Medicines is at the forefront of precision oncology research and development.

For more information about Revolution Medicines and its innovative approach to cancer treatment, please visit their website at https://www.revmed.com.

Drawdown (Underwater) Chart

Drawdown / Underwater Chart for RVMD - Revolution Medicines  - Stock & Dividends

Overall Trend and Yearly Seasonality

Drawdown / Underwater Chart for RVMD - Revolution Medicines  - Stock & Dividends

RVMD Stock Overview

Market Cap in USD 6,167m
Sector Healthcare
Industry Biotechnology
GiC SubIndustry Biotechnology
TER 0.00%
IPO / Inception 2020-02-13

RVMD Stock Ratings

Growth 5y 19.8
Fundamental -
Dividend -
Rel. Performance vs Sector 4.16
Analysts 4.67/5
Fair Price Momentum 43.80 USD
Fair Price DCF -

RVMD Dividends

Dividend Yield 12m 0.00%
Yield on Cost 5y 0.00%
Dividends CAGR 5y 0.00%
Payout Consistency 0.0%

RVMD Growth Ratios

Growth 12m 71.66%
Growth Correlation 12m 51%
Growth Correlation 3m 41%
CAGR 5y 11.06%
CAGR/Mean DD 5y 0.26
Sharpe Ratio 12m 1.00
Alpha vs SP500 12m 43.75
Beta vs SP500 5y weekly 1.22
ValueRay RSI 92.79
Volatility GJR Garch 1y 57.48%
Price / SMA 50 16.03%
Price / SMA 200 47.9%
Current Volume 1583.9k
Average Volume 20d 2239.9k

External Links for RVMD Stock

News
Wall Street JournalBenzingaYahoo Finance
Tweets
XStocktwits
Fund Manager Positions
DataromaStockcircle
What is the price of RVMD stocks?
As of July 19, 2024, the stock is trading at USD 46.04 with a total of 1,583,932 shares traded.
Over the past week, the price has changed by +6.21%, over one month by +22.06%, over three months by +28.50% and over the past year by +71.98%.
What are the forecast for RVMD stock price target?
According to ValueRays Forecast Model, RVMD Revolution Medicines will be worth about 49 in July 2025. The stock is currently trading at 46.04. This means that the stock has a potential upside of +6.47%.
Issuer Forecast Upside
Wallstreet Target Price 45.6 -1.06
Analysts Target Price 36 -21.8
ValueRay Target Price 49 6.47